Oxycodone Depot Lannacher

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxycodone Depot Lannacher (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodone Depot Lannacher, is an opioid analgesic presented as a depot formulation for oral use. It is employed in the management of moderate to severe pain, particularly when continuous long‑term analgesia is required, and is suitable for adult patients.

GNH India supplies Oxycodone Depot Lannacher as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone Depot Lannacher is an opioid analgesic that acts on the central nervous system to control pain.

Chronic cancer‑related pain: provides sustained relief over several days, reducing the need for frequent dosing.
Post‑operative pain after major surgery: maintains steady analgesia during the critical recovery period.
Severe non‑cancer chronic pain: offers continuous opioid coverage when other regimens are insufficient.

How It Works

Oxycodone Hydrochloride binds primarily to μ‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that decrease neuronal excitability and reduce the perception of pain. This receptor activation also modulates neurotransmitter release, contributing to its analgesic effect.

Side Effects

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects

Constipation: reduced gastrointestinal motility.
Nausea and vomiting: stimulation of the chemoreceptor trigger zone.
Drowsiness or sedation: central nervous system depression.
Dry mouth: decreased salivary secretion.
Dizziness: orthostatic hypotension or vestibular effects.
Pruritus: histamine release at the skin.

Serious or Rare Side Effects

Respiratory depression: reduced response to carbon dioxide.
Severe hypotension: profound vasodilation.
Opioid use disorder: dependence and addiction potential.
Adrenal insufficiency: suppression of the hypothalamic‑pituitary‑adrenal axis.
Seizures: lowered seizure threshold in susceptible individuals.
Anaphylaxis: acute Ig‑mediated hypersensitivity reaction.

Precautions & Warnings

When prescribing Oxycodone Depot Lannacher, clinicians should consider several safety aspects.

Assess pain severity and opioid tolerance: ensure the patient requires long‑acting opioid therapy.
Evaluate respiratory function: patients with compromised breathing are at higher risk of depression.
Review concomitant CNS depressants: avoid additive sedation or respiratory effects.
Monitor for signs of dependence: assess for misuse or addiction behaviors.
Adjust for renal or hepatic impairment: dose may need modification based on organ function.
Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Oxycodone Depot Lannacher can interact with a range of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines or other sedative‑hypnotics: combined use can cause profound respiratory depression.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase oxycodone plasma concentrations.
Opioid antagonists (e.g., naloxone): can precipitate acute withdrawal.

Moderate Interactions (Monitor Closely)

CNS depressants such as antihistamines or muscle relaxants: may enhance sedation.
CYP2D6 inhibitors (e.g., fluoxetine, quinidine): can reduce conversion to active metabolites.
Diuretics: may potentiate hypotensive effects.
Alcohol: additive central nervous system depression.
Serotonergic agents: risk of serotonin syndrome when combined with opioids.

Frequently Asked Questions

Oxycodone Depot Lannacher is a long‑acting opioid formulation indicated for the management of moderate to severe pain, including chronic cancer‑related pain, post‑operative pain after major surgery, and severe non‑cancer chronic pain when continuous analgesia is required.

Oxycodone hydrochloride binds to μ‑opioid receptors in the brain and spinal cord, activating inhibitory G‑protein pathways that lower neuronal excitability and diminish the transmission of pain signals, resulting in analgesia.

The dose of Oxycodone Depot Lannacher is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. No fixed regimen is provided here.

Opioids, including oxycodone, are generally contraindicated during pregnancy because of potential fetal dependence and neonatal respiratory depression. Breastfeeding while using oxycodone is discouraged unless the benefits outweigh the risks and the infant is closely monitored.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with immediate‑release opioids, the depot formulation provides sustained plasma concentrations over several days, reducing dosing frequency. This can improve adherence and maintain steadier pain control, though it requires careful monitoring for accumulation and delayed clearance.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and excessive heat to maintain potency and stability.

The depot formulation is administered orally as a single dose that releases oxycodone gradually over several days. Administration should follow the prescribing information and be performed by qualified healthcare personnel.

The most serious risks include respiratory depression, severe hypotension, opioid dependence or addiction, and rare events such as adrenal insufficiency or anaphylaxis. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to oxycodone or any formulation component, those with significant respiratory compromise, untreated severe asthma, or acute head injury should avoid this medication. It is also contraindicated in individuals with a history of opioid misuse without close supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.